SER
SER
AMEX · Biotechnology

Serina Therapeutics Inc.

$2.27
-0.34 (-13.03%)
Financial Highlights (FY 2026)
Revenue
84.2K
Net Income
-16,778,258
Gross Margin
71.8%
Profit Margin
-19,894.6%
Rev Growth
-26.3%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 71.8% 71.8% 66.4% 66.4%
Operating Margin -30,442.9% -27,398.6% -27.0% -31.0%
Profit Margin -19,894.6% -18,899.9% -29.1% -28.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 84.2K 114.3K 4.38M 4.18M
Gross Profit 60.5K 82.1K 2.91M 2.78M
Operating Income -25,641,716 -31,321,314 -1,184,186 -1,293,566
Net Income -16,778,258 -20,494,614 -1,275,702 -1,196,723
Gross Margin 71.8% 71.8% 66.4% 66.4%
Operating Margin -30,442.9% -27,398.6% -27.0% -31.0%
Profit Margin -19,894.6% -18,899.9% -29.1% -28.6%
Rev Growth -26.3% -26.3% +7.3% +19.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 3.35M 3.27M
Total Equity 12.66M 11.81M
D/E Ratio 0.26 0.28
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -5,225,542 -6,737,601 -1,970,058 -1,901,119
Free Cash Flow -1,043,157 -876,007